SIAG
MTNB icon

Signet Investment Advisory Group’s Matinas BioPharma MTNB Stock Holding History

Signet Investment Advisory Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed -$1K – 152
2020
Q4 		$1K Buy
+20
New +$926 ﹤0.01% 212

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Signet Investment Advisory Group's MTNB Position: Q1 2021 in Review

Signet Investment Advisory Group sold out of Matinas BioPharma (MTNB) in Q1 2021, closing a stake of 20 shares — an estimated $1K sold.

Signet Investment Advisory Group first reported a position in MTNB in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 80 funds tracked by Wall St. Rank hold MTNB as of Q1 2021.

  • Signet Investment Advisory Group reported no remaining Matinas BioPharma position as of Q1 2021 after selling out during the quarter.
  • Signet Investment Advisory Group sold 20 Matinas BioPharma shares in Q1 2021, an estimated $1K.
  • Signet Investment Advisory Group first reported a position in Matinas BioPharma in Q4 2020 and held it in 1 quarter.
  • Signet Investment Advisory Group's Matinas BioPharma position peaked at $1K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2021.

Based on Signet Investment Advisory Group's 13F filing for Q1 2021, filed 11 May 2021.